Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to -$10.6 million.

  • Inhibikase Therapeutics' Cash from Operations fell 11701.52% to -$10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.6 million, marking a year-over-year decrease of 4854.27%. This contributed to the annual value of -$19.1 million for FY2024, which is 587.79% down from last year.
  • Per Inhibikase Therapeutics' latest filing, its Cash from Operations stood at -$10.6 million for Q3 2025, which was down 11701.52% from -$5.6 million recorded in Q2 2025.
  • In the past 5 years, Inhibikase Therapeutics' Cash from Operations ranged from a high of -$2.0 million in Q3 2021 and a low of -$10.6 million during Q3 2025
  • Moreover, its 5-year median value for Cash from Operations was -$4.2 million (2021), whereas its average is -$4.7 million.
  • As far as peak fluctuations go, Inhibikase Therapeutics' Cash from Operations plummeted by 14582838.49% in 2021, and later skyrocketed by 3524.89% in 2024.
  • Inhibikase Therapeutics' Cash from Operations (Quarter) stood at -$4.1 million in 2021, then grew by 13.17% to -$3.6 million in 2022, then rose by 3.2% to -$3.4 million in 2023, then crashed by 55.28% to -$5.3 million in 2024, then plummeted by 98.16% to -$10.6 million in 2025.
  • Its last three reported values are -$10.6 million in Q3 2025, -$5.6 million for Q2 2025, and -$4.1 million during Q1 2025.